Evaluación de farmacovigilancia en pacientes adultos ingresados al área de hospitalización y consulta externa de medicina interna del Hospital General III D.E “Tarqui” del cantón Cuenca, durante el periodo enero - mayo de 2022

Abstract

Pharmacovigilance is the science that involves several health professionals for the risk-benefit assessment of medications, one of its application methods is intensive hospital pharmacovigilance, the same that facilitates knowledge of the incidence of ADRs and infers about possible risk factors involved. Objective: To evaluate the pharmacovigilance system applied in adult patients admitted to the hospitalization area and internal medicine external consultation of the General Hospital III D.E "Tarqui" of the Cuenca canton, during the period January - May 2022. Methods: A descriptive and observational cross-sectional study was carried out, with an initial statistical analysis of the adverse events reported from the year 2018 to the year 2021, determining the prevalence of the ADRs reported and the suspected causative drugs. Health personnel working in the institution were encouraged to apply the pharmacovigilance system by including informative strategies in their daily work, in order to increase the number of notifications of adverse events, avoiding omission and overcoming under-reporting. existing, activities carried out during the period January - May 2022. Finally, the respective statistical analysis was carried out with the data obtained from this last period of pharmaceutical monitoring, allowing to evaluate the operation of the pharmacovigilance system in the hospital with the benefits provided by the strategies used. Results: The results showed that the most frequent adverse reaction that occurs in the studied population of patients of the Military Hospital of the city of Cuenca is nausea with a percentage of 27.3%. The medication that most frequently produces an adverse event corresponds to tramadol with 33.3%, 12 notifications were obtained during the 5 months that included the follow-up period; in such a way that, at the end of the current year, the number of notifications may be increased up to a value of 3.5 times higher than the total figure reported in 2019.